Ed Kaye, departing CEO of Stoke Therapeutics

Stoke CEO Ed Kaye to de­part short­ly af­ter ink­ing Bio­gen pact and be­fore its first Phase 3 tri­al

In a sur­prise move, the long­time CEO of Stoke Ther­a­peu­tics is leav­ing the com­pa­ny, weeks be­fore the Phase 3 tri­al of its lead drug is …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.